KRAS mutations G12/G13 are observed in about 35–45% of CRC patients [111,117] and the first-line of treatment relies on a combination of chemotherapy of fluoropyrimidine with oxaliplatin or irinotecan [111]. The gene discussed is KRAS; the disease is colorectal carcinoma.